AP2005003393A0 - 3-(1-Ä3-(1,3-benzothiazol-6-yl) ropylcarbamoylÜcycloalkyl) propanoic acid derivatives as NEP inhibitors. - Google Patents

3-(1-Ä3-(1,3-benzothiazol-6-yl) ropylcarbamoylÜcycloalkyl) propanoic acid derivatives as NEP inhibitors.

Info

Publication number: AP2005003393A0
Authority: AP; ARIPO
Prior art keywords: ropylcarbamoylücycloalkyl; benzothiazol; acid derivatives; propanoic acid; nep inhibitors
Prior art date: 2003-03-14

Application number

AP2005003393A

Other languages

English (en)

Inventor

Hepworth David

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-14

Filing date

2004-03-09

Publication date

2005-09-30

2003-03-14 Priority claimed from GB0305916A external-priority patent/GB0305916D0/en

2003-12-16 Priority claimed from GB0329143A external-priority patent/GB0329143D0/en

2004-03-09 Application filed by Pfizer filed Critical Pfizer

2005-09-30 Publication of AP2005003393A0 publication Critical patent/AP2005003393A0/xx

Links

XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Pulmonology (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pregnancy & Childbirth (AREA)
Vascular Medicine (AREA)

AP2005003393A 2003-03-14 2004-03-09 3-(1-Ä3-(1,3-benzothiazol-6-yl) ropylcarbamoylÜcycloalkyl) propanoic acid derivatives as NEP inhibitors. AP2005003393A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0305916A GB0305916D0 (en)	2003-03-14	2003-03-14	New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors
GB0329143A GB0329143D0 (en)	2003-12-16	2003-12-16	Novel pharmaceuticals
PCT/IB2004/000822 WO2004080985A1 (fr)	2003-03-14	2004-03-09	Derives d'acide 3-(1-[3-(1,3-benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoique agissant comme inhibiteurs de la nep

Publications (1)

Publication Number	Publication Date
AP2005003393A0 true AP2005003393A0 (en)	2005-09-30

Family

ID=32992599

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2005003393A AP2005003393A0 (en)	2003-03-14	2004-03-09	3-(1-Ä3-(1,3-benzothiazol-6-yl) ropylcarbamoylÜcycloalkyl) propanoic acid derivatives as NEP inhibitors.

Country Status (25)

Country	Link
US (1)	US20040180941A1 (fr)
EP (1)	EP1606272A1 (fr)
JP (1)	JP3923512B2 (fr)
KR (1)	KR20050110003A (fr)
AP (1)	AP2005003393A0 (fr)
AR (1)	AR043551A1 (fr)
AU (1)	AU2004220269A1 (fr)
BR (1)	BRPI0408377A (fr)
CA (1)	CA2519072A1 (fr)
CL (1)	CL2004000512A1 (fr)
EA (1)	EA200501204A1 (fr)
EC (1)	ECSP056017A (fr)
HR (1)	HRP20050797A2 (fr)
IS (1)	IS8003A (fr)
MA (1)	MA27720A1 (fr)
MX (1)	MXPA05009788A (fr)
NL (1)	NL1025709C2 (fr)
NO (1)	NO20054169L (fr)
OA (1)	OA13039A (fr)
PA (1)	PA8597401A1 (fr)
PE (1)	PE20050310A1 (fr)
TN (1)	TNSN05227A1 (fr)
TW (1)	TW200504038A (fr)
UY (1)	UY28226A1 (fr)
WO (1)	WO2004080985A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060024241A1 (en) *	2004-08-02	2006-02-02	Bebaas, Inc.	Vitamin B12 compositions
WO2006027680A1 (fr) *	2004-09-10	2006-03-16	Pfizer Limited	Derives d'acide 3-(1-carbamoylcyclohexyl)propionique comme inhibiteurs de l'enzyme endopeptidase neutre
NZ555334A (en)	2004-12-24	2010-05-28	Spinifex Pharm Pty Ltd	Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
CA2616366A1 (fr)	2005-07-29	2007-02-08	Concert Pharmaceuticals Inc.	Nouveaux composes pharmaceutiques
US20130131007A1 (en)	2005-09-07	2013-05-23	Bebaas, Inc.	Vitamin b12 compositions
US20070178141A1 (en) *	2005-09-07	2007-08-02	Bebaas, Inc.	Vitamin B12 compositions
JP5230595B2 (ja) *	2006-03-20	2013-07-10	スピニフェクスファーマシューティカルズピーティーワイリミテッド	炎症性疼痛の治療または予防の方法
EP2051696A2 (fr) *	2006-08-18	2009-04-29	Morton Grove Pharmaceuticals, Inc.	Compositions liquides stables de lévétiracétam et procédés
KR101177866B1 (ko)	2011-03-24	2012-08-28	주식회사 케이엠더블유	케이블 접속 장치
JP2021527875A (ja) *	2018-06-14	2021-10-14	アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａＵＫＬｉｍｉｔｅｄ	Ｃｇｍｐ特異的ホスホジエステラーゼ５阻害剤の薬学的組成物により勃起不全を治療するための方法
CN112997258A (zh) *	2018-06-14	2021-06-18	阿斯利康(英国)有限公司	用cGMP特异性磷酸二酯酶5抑制剂药物组合物治疗勃起功能障碍的方法
WO2020064173A1 (fr)	2018-09-25	2020-04-02	Antabio Sas	Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne
WO2021091908A1 (fr) *	2019-11-08	2021-05-14	Vella Bioscience, Inc.	Compositions contenant du cannabidiol (cbd) à action périphérique et leurs utilisations pour améliorer la fonction sexuelle féminine ou traiter des troubles sexuels féminins
GB202402524D0 (en) *	2024-02-22	2024-04-10	Futura Medical Developments Ltd	Topical composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2503059A (en) *		1950-04-04		Nxchj
US2599000A (en) *	1950-09-02	1952-06-03	Smith Kline French Lab	Nu, nu-disubstituted-beta-halo-alkylamines
US3238215A (en) *	1963-10-17	1966-03-01	Sterling Drug Inc	1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
IT1066857B (it) *	1965-12-15	1985-03-12	Acraf	Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3511836A (en) *	1967-12-13	1970-05-12	Pfizer & Co C	2,4,6,7-tetra substituted quinazolines
NL175059C (nl) *	1974-02-23		Boehringer Mannheim Gmbh	Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
US4026894A (en) *	1975-10-14	1977-05-31	Abbott Laboratories	Antihypertensive agents
US4188390A (en) *	1977-11-05	1980-02-12	Pfizer Inc.	Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) *	1978-02-06	1979-11-02	Synthelabo	Amides d'alkylene-diamines et leur application en therapeutique
IT1094076B (it) *	1978-04-18	1985-07-26	Acraf	Cicloalchiltriazoli
JPS56110665A (en) *	1980-02-08	1981-09-01	Yamanouchi Pharmaceut Co Ltd	Sulfamoyl-substituted phenetylamine derivative and its preparation
DE3528032A1 (de) *	1985-08-05	1987-02-05	Hoechst Ag	Verfahren zur herstellung 2-substituierter benzthiazole
PT100905A (pt) *	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
CA2189355A1 (fr) *	1995-03-01	1996-09-06	Yasuo Onoda	Derives d'imidazoquinazoline
GB9518953D0 (en) *	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
US6037346A (en) *	1997-10-28	2000-03-14	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EE200300469A (et) *	2001-03-28	2004-02-16	Pfizer Inc.	N-fenpropüültsüklopentüülasendatud glutaramiidi derivaadid kui NEP inhibiitorid FSAD puhul

2004
- 2004-03-08 PA PA20048597401A patent/PA8597401A1/es unknown
- 2004-03-09 AU AU2004220269A patent/AU2004220269A1/en not_active Abandoned
- 2004-03-09 OA OA1200500261A patent/OA13039A/en unknown
- 2004-03-09 AP AP2005003393A patent/AP2005003393A0/xx unknown
- 2004-03-09 HR HR20050797A patent/HRP20050797A2/hr not_active Application Discontinuation
- 2004-03-09 JP JP2006500337A patent/JP3923512B2/ja not_active Expired - Fee Related
- 2004-03-09 EP EP04718706A patent/EP1606272A1/fr not_active Withdrawn
- 2004-03-09 KR KR1020057017229A patent/KR20050110003A/ko not_active Ceased
- 2004-03-09 CA CA002519072A patent/CA2519072A1/fr not_active Abandoned
- 2004-03-09 MX MXPA05009788A patent/MXPA05009788A/es unknown
- 2004-03-09 BR BRPI0408377-6A patent/BRPI0408377A/pt not_active IP Right Cessation
- 2004-03-09 WO PCT/IB2004/000822 patent/WO2004080985A1/fr not_active Ceased
- 2004-03-09 EA EA200501204A patent/EA200501204A1/ru unknown
- 2004-03-10 PE PE2004000259A patent/PE20050310A1/es not_active Application Discontinuation
- 2004-03-11 AR ARP040100785A patent/AR043551A1/es unknown
- 2004-03-11 UY UY28226A patent/UY28226A1/es not_active Application Discontinuation
- 2004-03-12 US US10/800,065 patent/US20040180941A1/en not_active Abandoned
- 2004-03-12 NL NL1025709A patent/NL1025709C2/nl not_active IP Right Cessation
- 2004-03-12 CL CL200400512A patent/CL2004000512A1/es unknown
- 2004-03-12 TW TW093106666A patent/TW200504038A/zh unknown
2005
- 2005-08-29 IS IS8003A patent/IS8003A/is unknown
- 2005-09-07 NO NO20054169A patent/NO20054169L/no not_active Application Discontinuation
- 2005-09-14 EC EC2005006017A patent/ECSP056017A/es unknown
- 2005-09-14 TN TNP2005000227A patent/TNSN05227A1/fr unknown
- 2005-09-14 MA MA28498A patent/MA27720A1/fr unknown

Also Published As

Publication number	Publication date
CA2519072A1 (fr)	2004-09-23
NL1025709C2 (nl)	2005-03-14
CL2004000512A1 (es)	2005-01-21
MXPA05009788A (es)	2005-10-26
BRPI0408377A (pt)	2006-03-21
MA27720A1 (fr)	2006-01-02
EA200501204A1 (ru)	2006-06-30
AR043551A1 (es)	2005-08-03
WO2004080985A1 (fr)	2004-09-23
AU2004220269A1 (en)	2004-09-23
PA8597401A1 (es)	2005-05-24
JP2006526572A (ja)	2006-11-24
IS8003A (is)	2005-08-29
OA13039A (en)	2006-11-10
NO20054169L (no)	2005-12-07
UY28226A1 (es)	2004-11-08
NO20054169D0 (no)	2005-09-07
US20040180941A1 (en)	2004-09-16
JP3923512B2 (ja)	2007-06-06
KR20050110003A (ko)	2005-11-22
NL1025709A1 (nl)	2004-09-16
TW200504038A (en)	2005-02-01
ECSP056017A (es)	2006-01-27
EP1606272A1 (fr)	2005-12-21
PE20050310A1 (es)	2005-05-04
HRP20050797A2 (en)	2006-02-28
TNSN05227A1 (fr)	2007-06-11

Publication	Publication Date	Title
IL176189A0 (en)	2006-10-05	3-(4-benzyloxyphenyl) propanoic acid derivatives
IL191711A0 (en)	2008-12-29	1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors
IL173522A0 (en)	2006-07-05	Phenoxyacetic acid derivatives
ZA200606974B (en)	2008-04-30	Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
ZA200804762B (en)	2009-04-29	1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
PL377511A1 (pl)	2006-02-06	Pochodne kwasu migdałowego
PL377905A1 (pl)	2006-02-20	2,4-difluorowco-6-(C<v>2<D> -C<v>3<D> -alkilo)fenylo-podstawione pochodne kwasu tetramowego
PL376920A1 (pl)	2006-01-09	Podstawione pochodne 4-alkoksyoksazolu jako agoniści PPAR
DK2051962T3 (da)	2012-01-02	(3-amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)-eddikesyrederivater
ZA200805404B (en)	2009-11-25	3,-6-Dihydro-2-oxo-6H-(1,3,4) thiadiazine derivatives
NO20054169D0 (no)	2005-09-07	3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer.
IL178166A0 (en)	2006-12-31	1,3,4-oxadiazol-2-ones as ppar delta
ATE396724T1 (de)	2008-06-15	1h-thieno 2,3-c-pyrazol-derivate als kinase-i- hemmer
AU2003282804A1 (en)	2004-04-08	3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors
ZA200707933B (en)	2009-08-26	Substituted aryl 1.4-pyrazine derivatives
ATE369342T1 (de)	2007-08-15	2,5-disubstituierte 3-mercaptopentansaure
DE60324703D1 (de)	2008-12-24	Barbitursäure derivaten.
NO20053753D0 (no)	2005-08-04	Karboksylsyreforbindelser.
PL374461A1 (pl)	2006-10-30	Sposób otrzymywania pochodnych 13,14-dihydro-PGF
DK1487802T3 (da)	2011-04-04	2,3-diaryl-pyrazolidin-derivater som neurotensin-nedbrydende enzyminhibitorer
IL188111A0 (en)	2008-03-20	2,5-bis-diamimne [1,4] benzoquinone-derivatives
IL186457A0 (en)	2008-01-20	Process for the preparation of 9,10-dehydro-12,13-desoxyepothilone derivatives
DE602004008002D1 (de)	2007-09-20	Herstellungsverfahren für hochreines tricyclo-(5.2.1.0 2,6)dekan-2-Carboxylsäureester
AU2003250090A1 (en)	2004-02-09	2,4-dihydroxybenzoic acid derivatives
AP2005003462A0 (en)	2005-12-31	Process for preparing 3-aryl-2-hydroxy propanoic acid derivatives without resolution.